Univariate analysis | Multivariate analysis | ||||
Variables | No (%) | HR | P value | HR | P value |
(95% CI) | (95% CI) | ||||
Age | |||||
<50 years | 53 (20%) | 1 (Referent) | 1 (Referent) | ||
>50 years | 211 (80%) | 0.70 | 0.49 | 0.51 | 0.25 |
(0.25 - 1.92) | (0.17 - 1.59) | ||||
Nuclear grade | |||||
1 - 2 | 179 (68%) | 1 (Referent) | 1 (Referent) | ||
3 | 85 (32%) | 2.93 | 0.017 | 3.10 | 0.031 |
(1.21 - 7.09) | (1.11 - 8.69) | ||||
Lymphatic invasion | |||||
Negative | 134 (51%) | 1 (Referent) | 1 (Referent) | ||
Positive | 130 (49%) | 2.43 | 0.069 | 1.27 | 0.71 |
(0.93 - 6.34) | (0.36 - 4.56) | ||||
Venous invasion | |||||
Negative | 195 (74%) | 1 (Referent) | 1 (Referent) | ||
Positive | 69 (26%) | 1.39 | 0.47 | 0.55 | 0.31 |
(0.57 - 3.41) | (0.17 - 1.74) | ||||
Estrogen receptor | |||||
Negative | 39 (15%) | 1 (Referent) | 1 (Referent) | ||
Positive | 225 (85%) | 0.32 | 0.021 | 0.30 | 0.14 |
(0.12 - 0.84) | (0.06 - 1.50) | ||||
Progesterone receptor | |||||
Negative | 69 (26%) | 1 (Referent) | 1 (Referent) | ||
Positive | 195 (74%) | 0.41 | 0.054 | 0.72 | 0.65 |
(0.17 - 1.10) | (0.18 - 2.97) | ||||
HER2 | |||||
Negative | 218 (83%) | 1 (Referent) | 1 (Referent) | ||
Positive | 46 (17%) | 1.48 | 0.49 | 0.71 | 0.56 |
(0.49 - 4.45) | (0.22 - 2.28) | ||||
Lymph node involvement | |||||
Negative | 185 (70%) | 1 (Referent) | 1 (Referent) | ||
Positive | 79 (30%) | 3.32 | 0.0086 | 3.04 | 0.038 |
(1.36 - 8.13) | (1.07 - 8.67) | ||||
Tumor size | |||||
<20mm | 125 (47%) | 1 (Referent) | 1 (Referent) | ||
>20mm | 139 (53%) | 4.35 | 0.0091 | 3.01 | 0.070 |
(1.44 - 13.14) | (0.91 - 10.6) | ||||
PLR | |||||
<162.3 | 189 (72%) | 1 (Referent) | 1 (Referent) | ||
>162.3 | 75 (28%) | 2.39 | 0.052 | 3.60 | 0.012 |
(0.99 - 5.75) | (1.32 - 9.78) |